Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Recent & Breaking News (TSX:APLI)

IIROC Trading Halt - APLI

PR Newswire October 7, 2021

Appili Therapeutics Announces Overnight Marketed Equity Offering

Business Wire October 6, 2021

AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics

PR Newswire September 29, 2021

Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction

Business Wire September 29, 2021

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus(TM) for the Treatment of Mild-to-Moderate COVID-19

Business Wire September 23, 2021

Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus(TM) for COVID-19 Patients

Business Wire September 20, 2021

Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus(TM) Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients

Business Wire September 17, 2021

Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders

Business Wire September 8, 2021

Appili Therapeutics Announces Closing of $3.5 Million Funding Agreement

Business Wire August 18, 2021

Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange

Business Wire September 14, 2020

Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA

Business Wire September 11, 2020

Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC

Business Wire September 10, 2020

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021

Business Wire August 14, 2020

Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders

Business Wire August 13, 2020

Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.

Business Wire August 11, 2020

FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities

Business Wire August 10, 2020

Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Outbreak Control Agent Against COVID-19

Business Wire July 30, 2020

Appili Therapeutics Announces FY 2020 Annual and Financial Results

Business Wire June 24, 2020

Appili Therapeutics Commences Trading on the OTCQX Marketplace

Business Wire June 15, 2020

OTC Markets Group Welcomes Appili Therapeutics Inc. to OTCQX

PR Newswire June 15, 2020